Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer Therapy

Bi-weekly fluorouracil/epirubicin/cyclophosphamide regimen has long-term safety profile

According to investigators in Italy, "To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC₂₁ ) or administered every 2 weeks (FEC₁₄ including support with filgrastim, a granulocyte colony-stimulating factor) in a multicenter phase III randomized trial."

M. Venturini and colleagues explained, "A total of 1214 patients with early-stage...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications